ebomi
Colour theme
Sign in
Insider · CIK 0001356090 Also files as an issuer

Intrexon Corp

CIK 0001356090 Name as filed on the most recent filing

Filed as Intrexon Corp (29)

59 transaction lines · from 29 filings · filed 2011-01-14 to 2019-04-03 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2019-04-03 S, Open-market sale Synthetic Biologics, Inc.SYN 2 lines 61,907, disposed Open Form 4 filing 0001567619-19-008334
2019-04-02 S, Open-market sale Synthetic Biologics, Inc.SYN 2 lines 9,006, disposed Open Form 4 filing 0001567619-19-008334
2019-04-01 S, Open-market sale Synthetic Biologics, Inc.SYN 2 lines 27,924, disposed Open Form 4 filing 0001567619-19-008334
2019-01-15 S, Open-market sale Histogenics CorpHSGX 51,885, disposed Open Form 4 filing 0001567619-19-001160
2019-01-14 S, Open-market sale Histogenics CorpHSGX 64,081, disposed Open Form 4 filing 0001567619-19-001160
2019-01-11 S, Open-market sale Histogenics CorpHSGX 42,806, disposed Open Form 4 filing 0001567619-19-001160
2018-01-17 P, Open-market purchase AquaBounty Technologies, Inc.AQB 4,999,998, acquired Open Form 4 filing 0001140361-18-002633
2017-12-11 P, Open-market purchase Fibrocell Science, Inc.FCSC 3 lines 2,100,000, acquired Open Form 4 filing 0001140361-17-046077
2017-05-08 S, Open-market sale Soligenix, Inc.SNGX 2 lines 29,403, disposed Open Form 4 filing 0001140361-17-018903
2017-05-05 S, Open-market sale Soligenix, Inc.SNGX 2 lines 230,850, disposed Open Form 4 filing 0001140361-17-018903
2017-05-04 S, Open-market sale Soligenix, Inc.SNGX 3 lines 241,629, disposed Open Form 4 filing 0001140361-17-018903
2017-01-18 P, Open-market purchase AquaBounty Technologies, Inc.AQB 25,009,684, acquired Open Form 4 filing 0001140361-17-002429
2016-12-29 S, Open-market sale AmpliPhi Biosciences CorpAPHB 2 lines 18,900, disposed Open Form 4 filing 0001140361-16-091123
2016-12-28 S, Open-market sale AmpliPhi Biosciences CorpAPHB 2 lines 39,771, disposed Open Form 4 filing 0001140361-16-091123
2016-12-27 S, Open-market sale AmpliPhi Biosciences CorpAPHB 2 lines 25,704, disposed Open Form 4 filing 0001140361-16-091123
2016-06-30 P, Open-market purchase Oragenics IncOGEN 1,166,666, acquired Open Form 4 filing 0001140361-16-071479
2015-09-02 P, Open-market purchase Synthetic Biologics, Inc.SYN 3,000,000, acquired Open Form 4 filing 0001140361-15-034452
2015-07-27 P, Open-market purchase Fibrocell Science, Inc.FCSC 3 lines 5,660,725, acquired Open Form 4 filing 0001140361-15-028723
2015-03-16 P, Open-market purchase AmpliPhi Biosciences CorpAPHB 2,300,000, acquired Open Form 4 filing 0001140361-15-012497
2015-02-09 P, Open-market purchase Ziopharm Oncology IncZIOP 12,600,000, acquired Open Form 4 filing 0001140361-15-005105
2014-06-04 P, Open-market purchase Fibrocell Science, Inc.FCSC 1,160,000, acquired Open Form 4 filing 0001140361-14-024707
2014-01-24 P, Open-market purchase Fibrocell Science, Inc.FCSC 4,999,999, acquired Open Form 4 filing 0001140361-14-003401
2013-12-17 P, Open-market purchase Synthetic Biologics, Inc.SYN 2 lines 2,500,000, acquired Open Form 4 filing 0001140361-13-047006
2013-11-20 P, Open-market purchase Oragenics IncOGEN 2 lines 3,106,225, acquired Open Form 4 filing 0001140361-13-043957
2013-10-29 P, Open-market purchase Ziopharm Oncology IncZIOP 10,000,001, acquired Open Form 4 filing 0001140361-13-040086
2013-10-01 P, Open-market purchase Fibrocell Science, Inc.FCSC 2 lines 14,999,998, acquired Open Form 4 filing 0001140361-13-037699
2013-09-30 P, Open-market purchase Oragenics IncOGEN 7,945,530, acquired Open Form 4 filing 0001140361-13-037608
2013-07-26 P, Open-market purchase Fibrocell Science, Inc.FCSC 7,499,999, acquired Open Form 4 filing 0001140361-13-029527
2012-11-07 P, Open-market purchase Ziopharm Oncology IncZIOP Not reported Open Form 4 filing 0001140361-12-046492
2012-10-29 P, Open-market purchase Synthetic Biologics, Inc.SYN 5,000,000, acquired Open Form 4 filing 0001140361-12-045067
2012-07-31 P, Open-market purchase Oragenics IncORNI 1,286,333, acquired Open Form 4 filing 0001140361-12-034892
2012-01-20 P, Open-market purchase Ziopharm Oncology IncZIOP 9,999,990, acquired Open Form 4 filing 0001140361-12-003409
2011-08-23 P, Open-market purchase Ziopharm Oncology IncZIOP 191,087, acquired Open Form 4 filing 0001140361-11-043686

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. INTREXON CORP, insider transactions. Retrieved 2026-08-24 from https://ebomi.com/insider/0001356090

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.